News

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on…

4 months ago

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will…

4 months ago

Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024

CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…

4 months ago

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News…

4 months ago

Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP

LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company…

4 months ago

Senzime: Year-end Report January – December 2023

UPPSALA, SWEDEN / ACCESSWIRE / February 15, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Press release: Uppsala, February 15, 2024. Senzime AB (publ):s…

4 months ago

GE HealthCare Management to Present at Upcoming Investor Conferences

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), is announcing today that its Vice President and Chief Financial Officer, Jay Saccaro, will be…

4 months ago

Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information

Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite…

4 months ago

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024…

4 months ago

ESO Appoints Joy Brown to Board of Directors

Accomplished executive brings 20+ years of experience leading transformative data intelligence initiatives across industries.AUSTIN, Texas--(BUSINESS WIRE)--ESO, a leading data and…

4 months ago